Robert Paul Floyd

US Patent:

6346529, Feb 12, 2002

Filed:

Apr 15, 1998

Appl. No.:

09/060670

Inventors:

Robert A. Floyd - Oklahoma City OK
Raymond F. Schinazi - Decatur GA

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK

International Classification:

A61K 3154

US Classification:

5142262, 5142242, 5142248

Abstract:

A method for using thiazine dyes, especially methylene blue, alone or in combination with low levels of light, to selectively inactivate or inhibit intracellular replication of specific viruses, especially human immunodeficiency virus. Examples of useful thiazine dyes are methylene blue, azure A, azure C, toluidine blue O, and thionine. The preferred dye at this time is methylene blue. Methylene blue is FDA approved for topical, i. v. , and oral administration, and has minimal side effects. Since methylene blue absorbs in the red wavelengths, i. e. , approximately 670 nm, which penetrates tissue much better than other lower wavelengths, light penetrating the skin to the capillaries at the surface can be used to enhance the activity of the dye.

US Patent:

6346544, Feb 12, 2002

Filed:

Feb 27, 2001

Appl. No.:

09/794292

Inventors:

Kenneth L. Hensley - Oklahoma City OK
Robert A. Floyd - Oklahoma City OK

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK

International Classification:

A61K 31355

US Classification:

514458

Abstract:

The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the protection of cardiovascular tissue from nitrative stress. While mechanisms other than scavenging of reactive nitrogen species may be involved, desmethyl tocopherols exhibit significant protection and may be utilized to treat or help prevent cardiovascular particularly arterial vascular disease. The desmethyl tocopherols may be administered dietarily or parenterally when a more direct dosage is desired. Both routes may be utilized together or separately to optimize therapeutic and prophylactic benefits. The lessening of damage induced by reactive nitrogen species leads to the lessening of arterial blockage in thrombosis.

US Patent:

6403627, Jun 11, 2002

Filed:

Jul 20, 1999

Appl. No.:

09/357297

Inventors:

John M. Carney - Lexington KY
Robert A. Floyd - Oklahoma City OK

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK
University of Kentucky Foundation - Lexington KY

International Classification:

A61K 31415

US Classification:

514400, 514576, 514658

Abstract:

Spin trapping compositions in general have now been discovered to be effective in treating a variety of disorders, including disorders such as those arising from ischemia, infection, inflammation, exposure to radiation or cytotoxic compounds, not just of the central and peripheral nervous systems but of peripheral organ disease having a wide variety of etiologies. In the preferred embodiment, the compositions for treating tissue damage from ischemia contain PBN, or active derivatives thereof, in a suitable pharmaceutical carrier for intravenous, oral, topical, or nasal/pulmonary administration. Other preferred spin-trapping agents include 5,5-dimethyl pyrroline N-oxide (DMPO), -(4-pyridyl-1-oxide)-N-tert-butylnitrone (POBN), and (TEMPO) and spin-trapping derivatives thereof. Examples of derivatives of PBN include halogenated derivatives, bifunctional derivatives, conjugates with drugs or targeting molecules, dimers and cyclodextran polymers of PBN. Many different disorders can be treated using these compounds, including diseases or disorders of the central and peripheral nervous systems, and disorders arising from ischemia, infection, inflammation, oxidation from exposure to radiation or cytotoxic compounds, as well as due to naturally occurring processes such as aging.

US Patent:

6569902, May 27, 2003

Filed:

Mar 28, 2001

Appl. No.:

09/819570

Inventors:

Robert A. Floyd - Oklahoma City OK
Yashige Kotake - Oklahoma City OK
Kenneth L. Hensley - Oklahoma City OK
Dai Nakae - Nara, JP

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK

International Classification:

A01N 3302

US Classification:

514638, 514640, 514645, 564248, 564300

Abstract:

PBN (-phenyl-tert-butylnitrone), and its derivatives nitrone-based free radical traps, significantly reduce preneoplastic nodule development as well as inhibit hepatocellular carcinoma (HCC) formation at very low levels. The involvement of reactive oxygen species (ROS) in cancer development has been strongly implicated for many years. The involvement of ROS has been strongly implicated in cancer development is a model system where feeding a choline deficiency (CD) diet to rats leads to hepatocellular carcinoma (HCC) development. Administering PBN in the drinking water inhibits HCC formation. Preneoplastic nodule growth in the liver is significantly suppressed by administering PBN, or some of its natural metabolites, in the diet. The effectiveness of PBN in preventing HCC development in the CD liver model is considered due to its prevention of tumor development after the target cells have already been initiated, i. e. genetically changed into tumor cells.

US Patent:

7517669, Apr 14, 2009

Filed:

Nov 1, 2001

Appl. No.:

10/003669

Inventors:

Robert H. Broyles - Oklahoma City OK, US
Robert A. Floyd - Oklahoma City OK, US

International Classification:

C12P 21/06

US Classification:

435 691, 435455, 424 932, 424 9321

Abstract:

A method is described for regulating gene expression related to iron metabolism to ameliorate diseases that include sickle cell disease, cancers, neurodegenerative diseases, Friedreich's ataxia and other neuromuscular disorders, and atherosclerosis. This approach is illustrated by recent findings that show that ferritin-H, an iron-binding protein that is present in cell nuclei, can repress the human β-globin gene, the gene that is mutated in sickle cell disease. Increased expression of ferritin-H or a related ferritin-family peptide, given to effected cells either as the peptide itself (or a part thereof), as an expression clone of the ferritin-H-subfamily gene, or via a gene regulator that increases expression of the ferritin-H-subfamily gene itself, prevents or ameliorates expression of the disease state in disorders where increased availability of iron is implicated in the etiology of the disease, including those named above.

US Patent:

7718699, May 18, 2010

Filed:

Mar 6, 2006

Appl. No.:

11/369179

Inventors:

Robert H. Broyles - Oklahoma City OK, US
Robert A. Floyd - Oklahoma City OK, US
Visar Belegu - Baltimore MD, US
Austin C. Roth - Sunderland MA, US

International Classification:

A61K 31/20

US Classification:

514560

Abstract:

The present invention relates generally to the fields of molecular biology and pharmacology. More particularly, it concerns the use of abscissic acid to treat various diseases, including neurodegenerative diseases and neuromuscular diseases.

US Patent:

8420595, Apr 16, 2013

Filed:

Jul 25, 2007

Appl. No.:

12/374970

Inventors:

Richard Dana Kopke - Oklahoma City OK, US
Robert A. Floyd - Oklahoma City OK, US

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK

International Classification:

A61K 38/06
A61K 31/15
A61K 31/195
A61K 38/00
A61K 31/41
A61P 27/16

US Classification:

514 23, 514359, 514563, 514640

Abstract:

The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition includes compounds which function as free radical traps such as phenyl butyl nitrone (PBN), free radical scavengers, such as edaravone, resveratrol, ebselen and iron chelator and compounds from the family of antioxidant compounds including, but not limited to, N-acetylcysteine (NAC), Acetyl-L-Carnitine (ALCAR), glutathione monoethylester, ebselen, D-methionine and carbamathione. The compositions of the current invention may be delivered by injections or orally.

US Patent:

8633249, Jan 21, 2014

Filed:

Sep 2, 2009

Appl. No.:

12/552792

Inventors:

Rheal A. Towner - Piedmont OK, US
Robert A. Floyd - Oklahoma City OK, US

Assignee:

Oklahoma Medical Research Foundation - Oklahoma City OK

International Classification:

A01N 37/00
A61K 31/185
A01N 33/24
A61K 31/15
C07C 309/00

US Classification:

514576, 514640, 562 62

Abstract:

The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.